InvestorsHub Logo
Followers 21
Posts 1498
Boards Moderated 0
Alias Born 07/27/2011

Re: None

Tuesday, 09/06/2016 6:05:25 PM

Tuesday, September 06, 2016 6:05:25 PM

Post# of 2490
https://www.thestreet.com/story/13681634/1/here-s-why-cyclacel-pharmaceuticals-cycc-stock-is-surging-today.html?puc=stocktwits&cm_ven=STOCKTWITS&utm_source=dlvr.it&utm_medium=organic&utm_campaign=stocktwits


http://www.nasdaq.com/symbol/cycc/short-interest

https://www.thestreet.com/story/13674061/1/cyclacel-pharmaceuticals-cycc-stock-pops-h-c-wainwright-bullish.html


http://globenewswire.com/news-release/2016/09/06/869615/0/en/Cyclacel-s-CYC065-Demonstrates-Promising-Activity-in-MYCN-Addicted-Neuroblastoma-in-Preclinical-Data-Presented-at-Childhood-Cancer-2016.html

http://www.cyclacel.com/

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.
Our Pipeline

Applying its core strength in cell cycle biology, Cyclacel is advancing a pipeline of orally available, small molecule, investigational drugs designed to stop uncontrolled cell division. Sapacitabine, our lead drug candidate, is being evaluated in the SEAMLESS pivotal Phase 3 trial in elderly patients with acute myeloid leukemia under a Special Protocol Assessment agreement with the US Food and Drug Administration. For more information on our investigational drug programs and clinical trials, please go to the Research & Development tab above.
Learn more about our clinical trials:
Sapacitabine (CYC682)
An oral nucleoside analogue prodrug that acts through a novel mechanism.
Seliciclib (CYC202)
A novel, first-in-class, orally available, cyclin dependent kinase (CDK) inhibitor.
CYC065
A highly-selective, orally-available, 2nd generation inhibitor of cyclin dependent kinases (CDK) 2 and 9.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYCC News